SCHEMBL1633920

SCHEMBL1633920

CN1CCN(C(=O)c2cccc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc23)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.49
SMG1 Q96Q15 1/20 0.49
FGFR4 P22455 1/20 0.48
SYK P43405 2/20 0.48
CCNE1 P24864 4/20 0.47
CDK2 P24941 4/20 0.47
CCNT1 O60563 3/20 0.47
CDK9 P50750 3/20 0.47
IKBKB O14920 3/20 0.46
MEN1 O00255 1/20 0.46
PTPN7 P35236 1/20 0.46
HTT P42858 1/20 0.46
DUSP3 P51452 1/20 0.46
PTPN5 P54829 1/20 0.46
KMT2A Q03164 1/20 0.46
PTPN11 Q06124 1/20 0.46
JAK2 O60674 1/20 0.46
BRD4 O60885 1/20 0.46
CCNB2 O95067 2/20 0.46
CCNE2 O96020 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632748 0.91 MTOR (0.58) MTORSMG1SYKCDK2CCNT1
SCHEMBL12724211 0.89 MTOR (0.48) MTORSMG1SYKCCNE1CDK2
SCHEMBL1634662 0.88 MAPK10 (0.56) MTORSMG1SYKIKBKBJAK2
SCHEMBL1633935 0.85 MAPK10 (0.62) MTORSMG1FGFR4CCNE1CDK2
SCHEMBL1633187 0.84 MTOR (0.60) MTORSMG1FGFR4CCNE1CDK2
SCHEMBL1632623 0.83 MAPK10 (0.53) MTORSMG1FGFR4CCNE1CDK2
SCHEMBL1632609 0.83 CDK1 (0.48) MTORSMG1FGFR4SYKCDK2
SCHEMBL1633194 0.83 CDK1 (0.48) MTORSMG1FGFR4SYKCDK2
SCHEMBL1632614 0.83 CDK1 (0.48) MTORSMG1FGFR4SYKCDK2
SCHEMBL1632479 0.82 MTOR (0.45) MTORSMG1SYKCCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 MTOR 82/4885SMG1 1001/4885FGFR4 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.